Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Soleno Therapeutics Inc maintains a gross margin of 98.73%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 33.57%, while the net margin is 33.17%. These profitability ratios, combined with a Return on Equity (ROE) of 26.27%, provide a clear picture of how effectively SLNO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, SLNO competes directly with industry leaders such as TARS and SUPN. With a market capitalization of $2.76B, it holds a significant position in the sector. When comparing efficiency, SLNO's gross margin of 98.73% stands against TARS's 94.20% and SUPN's 76.39%. Such benchmarking helps identify whether Soleno Therapeutics Inc is trading at a premium or discount relative to its financial performance.
